ResMed SG&A increased by 2.6% to $285.66M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.5%, from $245.30M to $285.66M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 10.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $181.48M | $176.72M | $185.36M | $182.40M | $193.03M | $193.93M | $211.67M | $228.46M | $239.94M | $222.87M | $222.16M | $229.92M | $242.19M | $238.98M | $241.61M | $245.30M | $265.13M | $259.19M | $278.40M | $285.66M |
| QoQ Change | — | -2.6% | +4.9% | -1.6% | +5.8% | +0.5% | +9.1% | +7.9% | +5.0% | -7.1% | -0.3% | +3.5% | +5.3% | -1.3% | +1.1% | +1.5% | +8.1% | -2.2% | +7.4% | +2.6% |
| YoY Change | — | — | — | — | +6.4% | +9.7% | +14.2% | +25.2% | +24.3% | +14.9% | +5.0% | +0.6% | +0.9% | +7.2% | +8.8% | +6.7% | +9.5% | +8.5% | +15.2% | +16.5% |
Range$176.72M – $285.66M
CAGR+10.0%
Avg YoY Growth+10.8%
Median YoY Growth+9.1%
Current Streak2 quarters growth
Business Segments
| Segment | Q1 '26 |
|---|---|
| Sleep And Breathing Health | $149.51M |
| Residential Care Software | $35.56M |
| Total | $285.66M |
SG&A at Other Companies
Frequently Asked Questions
- What is ResMed's sg&a?
- ResMed (RMD) reported sg&a of $285.66M in Q1 2026.
- How has ResMed's sg&a changed year-over-year?
- ResMed's sg&a increased by 16.5% year-over-year, from $245.30M to $285.66M.
- What is the long-term trend for ResMed's sg&a?
- Over 4 years (2021 to 2025), ResMed's sg&a has grown at a 10.3% compound annual growth rate (CAGR), from $670.39M to $991.02M.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.